What Does Arcellx (ACLX) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Summary
A clinical-stage biotech developing anito-cel, a next-generation BCMA-targeting CAR-T cell therapy for multiple myeloma, which has signed a global commercialization partnership with Gilead Sciences...
Subscribe🏢 What does Arcellx do?
Arcellx (ACLX) is a clinical-stage biotech company developing next-generation CAR-T (chimeric antigen receptor T-cell) cell therapies for patients with multiple myeloma, a hard-to-treat blood cancer. Headquartered in Redwood City, California, the company was founded in 2014. While conventional CAR-T therapies typically recognize cancer cells via an scFv (single-chain variable fragment), Arcellx applies its proprietary "D-Domain" binding platform to attack BCMA (B-cell maturation antigen)-expressing cancer cells with greater stability and efficiency, giving it a differentiated technology. The company has signed a global commercialization partnership with Kite Pharma, a Gilead Sciences company, providing it with the backing of one of the world's largest pharmaceutical companies.
💰 How does it make money?
Arcellx is still a clinical-stage company with no commercial product revenue, as no product has been approved yet. The vast majority of its current revenue comes from partnership upfront payments and milestones from Gilead.
| Revenue Type | Share | Description |
|---|---|---|
| Partnership Upfront & Milestones | ~100% | Upfront payments and development milestones from the global anito-cel partnership with Gilead/Kite Pharma |
| Product Revenue (Future Expected) | - | Sales royalties and profit-sharing expected after anito-cel receives FDA approval |
Its lead pipeline asset, anito-cel (formerly CART-ddBCMA), is in a Phase 2/3 trial (the iMMagine-1 study) targeting patients with relapsed/refractory multiple myeloma. It has the potential to grow into a major blockbuster therapy if it receives FDA approval.
📐 Market cap and company size
Arcellx's market cap stands at $6.7B, roughly equivalent to About 2% of Samsung Electronics' market cap. With about 209 people employees, it is a small biotech. Upfront payments secured through the Gilead partnership are funding its clinical expenses, and it is a typical clinical-stage biotech with no product revenue yet.
📈 Arcellx outlook and stock performance
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe core momentum for Arcellx hinges on anito-cel's clinical results and FDA approval. The multiple myeloma treatment market is worth tens of billions of dollars annually, and demand for CAR-T therapies for patients refractory to existing treatments is rising sharply. With rivals Legend Biotech's Carvykti and Bristol-Myers Squibb's Abecma already approved, differentiated efficacy and safety data for anito-cel will be the key to market entry. Having a strong partner like Gilead backing the commercialization is another positive factor.
⚔️ Key competitive strengths and risks
Arcellx's differentiated D-Domain CAR-T technology and Gilead partnership are strengths, but regulatory and clinical risks, typical of clinical-stage biotech, are the key challenges.
💪 Key Competitive Strengths
⚠️ Key Risks
Competitors and related (beneficiary) stocks
Below are companies competing with Arcellx in the CAR-T cell therapy space, along with stocks tied to the multiple myeloma treatment ecosystem.
Competitors: Legend Biotech (LEGN) is a direct rival in the BCMA CAR-T market with Carvykti, approved together with J&J. Fate Therapeutics (FATE) is a competitor in the allogeneic (off-the-shelf) CAR-T space, while CRISPR Therapeutics (CRSP) develops gene-editing-based cell therapies. Bluebird Bio (BLUE) is a gene and cell therapy company, and Poseida Therapeutics (PSTV) is also a competitor in next-generation cell therapies.
Related (beneficiary) stocks: Gilead Sciences (GILD) is anito-cel's partner and would directly benefit upon approval. Bristol-Myers Squibb (BMY) holds Abecma, a multiple myeloma CAR-T, and Johnson & Johnson (JNJ) is Carvykti's partner. Amgen (AMGN) and Sanofi (SNY) are strong players in multiple myeloma treatments and share adjacent markets.
The table below provides real-time quotes and key metrics for competitors and related stocks at a glance.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 LEGN | Legend Biotech Corp ADR | $19.19 | -3.6% | $3.7B | - | 3.0 | -8.11% | - |
 FATE | Fate Therapeutics Inc | $2.33 | -4.5% | $279.2M | - | 1.8 | -60.75% | - |
 CRSP | CRISPR Therapeutics AG | $52.26 | -2.2% | $5.1B | - | 2.9 | -26.09% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences Inc | $144.81 | -0.6% | $179.6B | - | 15.2 | -20.57% | 2.24% |
| BMY | Bristol-Myers Squibb Co | $63.75 | -1.0% | $130.2B | 14.0 | 5.8 | 46.7% | 3.67% |
| JNJ | Johnson & Johnson | $266.35 | -0.3% | $641.9B | 30.9 | 7.5 | 25.74% | 2.02% |
| AMGN | AMGEN Inc | $382.47 | -2.3% | $206.8B | 23.8 | 17.7 | 91.47% | 2.64% |
| SNY | Sanofi ADR | $42.72 | -0.3% | $101.8B | 22.0 | 1.3 | 5.7% | 5.74% |
✅ Investor checklist
Arcellx is a company developing CAR-T cell therapies that extract immune cells from blood cancer patients, engineer them to attack cancer cells, and infuse them back into the patient. If successful, significant value can be created, but if it fails, the stock can drop sharply — a classic high-risk, high-reward biotech.
| Checkpoint | What to verify | Current status |
|---|---|---|
| 🧬 Clinical Data | Are the efficacy and safety data from the iMMagine-1 trial positive? | ✅ Early data positive, Phase 2/3 in progress |
| 🤝 Gilead Partnership | Is the partnership with Gilead progressing smoothly? | ✅ Global commercialization partnership ongoing |
| Cash Position | Is sufficient cash secured through clinical completion? | Operating capital secured via partnership upfront payments |
Clinical-stage biotechs are event-driven stocks that move sharply each time clinical results are released. Anito-cel's clinical data readouts, FDA approval timeline, and progress under the Gilead partnership are the key investment catalysts. Allocating a small share of your overall portfolio is prudent.
Arcellx is a biotech seeking to address the significant unmet medical need in multiple myeloma with innovative CAR-T technology, and is a high-risk, high-return investment with blockbuster potential if its clinical trials succeed.
Check out Arcellx's real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free